Aphton Corporation To Expand Licensing And Commercialization Agreements Into Europe For IGN311

Published: Feb 07, 2006

Aphton Corporation (Pink Sheets:APHT) announced today that its wholly-owned subsidiary, Igeneon, signed a letter of intent with Celltrion to amend their existing licensing and commercialization agreements for the clinical product candidate, IGN311, a humanized monoclonal antibody against the Lewis-Y carbohydrate antigen and Igeneon's next-generation antibody, IGN312.

Back to news